Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Rick Winningham Sells 5,500 Shares

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Rick Winningham sold 5,500 shares of the company’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $180.86, for a total transaction of $994,730.00. Following the sale, the director directly owned 8,893 shares of the company’s stock, valued at $1,608,387.98. This represents a 38.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Jazz Pharmaceuticals Trading Down 0.2%

Shares of Jazz Pharmaceuticals stock traded down $0.34 during trading on Thursday, hitting $175.74. The stock had a trading volume of 1,664,525 shares, compared to its average volume of 947,213. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. The company has a market capitalization of $10.68 billion, a PE ratio of -26.11, a P/E/G ratio of 8.49 and a beta of 0.29. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $182.99. The stock has a 50 day simple moving average of $136.90 and a 200 day simple moving average of $121.57.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.87 by $2.26. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The company had revenue of $1.13 billion during the quarter, compared to analyst estimates of $1.11 billion. During the same quarter in the prior year, the company earned $6.54 earnings per share. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. On average, research analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the stock. Vestal Point Capital LP bought a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter worth $127,344,000. Nuveen LLC acquired a new stake in shares of Jazz Pharmaceuticals in the first quarter valued at about $62,362,000. Fuller & Thaler Asset Management Inc. increased its stake in shares of Jazz Pharmaceuticals by 41.7% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company’s stock worth $165,245,000 after purchasing an additional 391,660 shares during the period. Schonfeld Strategic Advisors LLC increased its stake in shares of Jazz Pharmaceuticals by 592.1% in the third quarter. Schonfeld Strategic Advisors LLC now owns 436,443 shares of the specialty pharmaceutical company’s stock worth $57,523,000 after purchasing an additional 373,383 shares during the period. Finally, AQR Capital Management LLC boosted its stake in Jazz Pharmaceuticals by 62.1% during the 2nd quarter. AQR Capital Management LLC now owns 794,770 shares of the specialty pharmaceutical company’s stock valued at $84,341,000 after purchasing an additional 304,463 shares during the period. 89.14% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on JAZZ shares. Wall Street Zen upgraded Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, November 8th. Zacks Research upgraded shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Friday, August 15th. Truist Financial upped their price target on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a “buy” rating in a research note on Thursday, August 28th. Royal Bank Of Canada set a $194.00 price objective on Jazz Pharmaceuticals and gave the company an “outperform” rating in a research report on Monday. Finally, Bank of America upped their target price on Jazz Pharmaceuticals from $230.00 to $247.00 and gave the stock a “buy” rating in a research report on Tuesday. Fourteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $195.07.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.